HORMÆ Pharma develops new therapeutics against Epstein-Barr Virus 



Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that infects more than 90% of adult human population worldwide.

Chronic EBV infections are linked with malignancies of lymphoid and epithelial cell origins and with autoimmune disease such as multiple sclerosis. 

Company overview

HORMÆ Pharma is a privately hold biotech company that was founded in November 2020 in Lyon, France. The founders are scientists, who have a strong record in immunology, virology and medicinal chemistry as well as experience in the creation and management of biopharmaceutical companies. The company is developing small molecule therapeutics targeting the cellular receptor that control the latency/replication balance of EBV to prevent and treat EBV induced pathologies. 

The company’s program results from the work initially conducted by the INSERM team of two co-founders at the International Centre for Research in Infectiology (CIRI). The library of proprietary receptors ligands was designed and synthetized by the third co-founder at Edelris


Patrice André, MD, PhD.
Co-founder and President

  • Professor Emeritus at Lyon Sud - Charles Mérieux Medical School, Claude Bernard Lyon1 University, Lyon, France.
  • Senior PI at VIRIMI team, Inter-national Center for Research in Infectiology
  • Former head of the clinical virology laboratory at the Hospices Civils de Lyon.
  • Co-founder of Enyo Pharma
  • Author of more than 200 articles in peer reviewed journals
  • Co-inventor of nine patents

Scientific staff

Marlène Roy, PhD.

R&D project manager

  • Thesis in virology and genomics
  • Post-Doc at University College Dublin, Ireland,
  • Scientist and laboratory manager at Padenga Holdings Limited, a crocodile farm in Kariba, Zimbabwe, 
  • Co-inventor of one patent


Vincent Lotteau, PhD.

  • Research Director, Inserm
  • Former director of the «Fondamental and Clinical Immunology» Inserm Unit
  • Former team leader at the International Center for Research in Infectiology
  • Actual director of the BSL4 laboratory Inserm-Jean Mérieux
  • Co-founder of EnyoPharma
  • Co-inventor of 11 patents

Didier Roche, PhD. 

  • CSO at Edelris, a mid-size CRO he co-founded in 2005 and located in Lyon, France
  • >13 years of experience in the pharmaceutical industry in R&D at Novartis and Merck KGaA
  • Principal Inventor of 2 drug candidates
  • Author and co-author of 40 articles in peer reviewed journals
  • Co-inventor of 16 patents


Pre-seed series

  • Société d’Accélération du Transfert de Technologies de la région Auvergne Rhône Alpes, Pulsalys
  • TH INVESTMENT GmbH, Ketsch, Germany
  • THIM SAS, Lyon, France